Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We expect further bottom line improvement in 2024 |
| pipeline and continued momentum internationally for full year 2024, we expect revenue in the range of $37 million to $40 million and anticipate that our profitability momentum and positive cash generation will continue throughout the year |
| I'm excited to discuss the strong momentum that currently exists throughout our entire business, as well as our positive outlook for 2024 |
| And as Hadar mentioned in each session we are expecting 2024 to be also positive in all of the KPIs, including EBITDA |
| I am thrilled to report that we significantly exceeded those expectations |
| And we are very, very proud of it |
| Most importantly, we generated positive quarterly net income in the fourth quarter |
| In Q4, we also recorded positive adjusted EBITDA and cash flow from operations for the second consecutive quarter |
| And we're coming with a robust and a complete business model that helps our customers to grow |
| In addition, anticipate that our profitability momentum and positive cash generation will continue throughout the remainder of 2024 |
| As you can tell from our most recent results and expectations for 2024, we are confident in the upward trajectory of our overall business, as well as the current market dynamics and the opportunities that lay ahead |
| market environment is reasonably strong, and we have experienced large commercial wins both in the U.S |
| We're also seeing that the market awareness around Ketamine clinic is also a great opportunity for us |
| We're seeing some great demand for our service model, recurring model, either on a fixed lease or on a paper use |
| Moreover, our international business continued to perform extremely well |
| In addition, looking even further ahead, we remain focused on leading innovation within the TMS industry, increasing our confidence in BrainsWay's ability to continue capturing significant market share, both in the U.S |
| In closing, we believe BrainsWay is in the strongest position it has ever been in |
| environment for the market, which you noted is very positive |
| And we do believe that by activating more neurons in the brain in a shorter time will result with a better efficacy rates even from what we're seeing today |
| A second paper published in the Journal of Clinical Medicine highlighted Deep TMS for the treatment of late-life depression and included the positive result of a post-marketing study of 247 older adults suffering from major depressive disorder |
| Importantly, the commercial trends in our business continue to appear favorable |
| While the current FDA labeling does not extend to these older patients and further analysis is needed, we are very excited about these results as they suggest that BrainsWay’s Deep TMS can potentially treat depression in older adults patients |
| The compelling data from these studies involving a total of 220 Parkinson's disease patients showed that Deep TMS treatment led to significant improvement in motor symptoms as well as meaningful impact on non-motor aspects of daily living and mood symptoms |
| My confidence is around the pipeline that is continuing to grow, and it's a mix between enterprise account, current customers of BrainsWay that continue to grow with us, and that's a very good sign, but also new customers that are looking to adopt this technology |
| Should we expect to see some call it, low or mid or high single digits for 2024 on the adjusted EBITDA line as well? Ido Marom So we currently don't give guidance on EBITDA or profit, but we definitely had a very strong momentum during the second half of 2023 |
| In order to attain further growth, we continue to achieve significant progress in expanding the clinical and real-world evidence in support of Deep TMS in multiple large disease areas |
| In addition, we continue to be supported by an extremely strong budget, having added 2023 with 46.3 million in cash with no debt |
| So I think all those three factors can really, really put us in a good spot for 2024, and we see the pipeline |
| We are coming off very strong 2023 and are now forecasting 2024 top line growth of at least 16% |
| So there is a good adoption, specifically for a noninvasive technology like we are offering |
| Statement |
|---|
| Operating profit for the fourth quarter was $184,000 compared to an operating loss of $4.3 million for the same period in 2022 |
| From a reimbursement standpoint, there is a growing list of payers that have reduced the patient eligibility requirements for TMS treatment |
| Most recently, a major private insurer in Louisiana covering 1.9 million lives went from four failed medication trials to two |
Please consider a small donation if you think this website provides you with relevant information